Komori
Human Metabolome Technologies (6090) · InitiativeRestated

Commercialization of the Depression Biomarker Business Through a Licensing Agreement with Sysmex Corporation

First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2021.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20212017: 120172018: 020182019: 120192020: 120202021: 12021
Same theme, other companies
Upfront Contractual and Milestone Income from Development Rights LicensingA theme 3 companies write about · 0 as a headwind · 3 as a tailwind

0 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2021RestatedAnnual report

    「Grant of a non-exclusive license to patents related to the company's blood biomarker for major depressive disorder, phosphoethanolamine, and manufacture and sale of the product.」

    The company continues to disclose its license agreement with SYSMEX CORPORATION related to the major depressive disorder biomarker.
  2. FY2020RestatedAnnual report

    「Grant of a non-exclusive license to patents related to the company's blood biomarker for major depressive disorder, phosphoethanolamine, and manufacture and sale of the product.」

    The company continues to disclose its license agreement with SYSMEX CORPORATION related to the major depressive disorder biomarker.
  3. FY2019RestatedAnnual report

    「Grant of a non-exclusive license to patents related to the company's blood biomarker for major depressive disorder, phosphoethanolamine, and manufacture and sale of the product.」

    The company continues to disclose its license agreement with SYSMEX CORPORATION related to the depression biomarker.
  4. FY2017First statedAnnual report

    「The company recognized upfront consideration received in connection with entering into a license agreement with SYSMEX CORPORATION, with which it had previously been conducting joint research toward the commercialization of a biomarker for major depressive disorder.」

    The company describes the execution of a license agreement with SYSMEX CORPORATION and recognition of upfront consideration as progress toward commercialization of the depression biomarker business.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Commercialization of the Depression Biomarker Business Through a Licensing Agreement with Sysmex Corporation | Human Metabolome Technologies,Inc. (6090) | Komori